Alpine Immune Sciences, Inc. announced that it has received $25.274979 million in funding from Decheng Capital LLC, OrbiMed Advisors, L.L.C., Frazier Healthcare Partners, Alpine BioVentures, GP, LLC, BVF Partners LP, Aspire Capital Partners, LLC
January 18, 2019
Share
On January 18, 2019, Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) closed the transaction.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Companyâs approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Alpine Immune Sciences, Inc. announced that it has received $25.274979 million in funding from Decheng Capital LLC, OrbiMed Advisors, L.L.C., Frazier Healthcare Partners, Alpine BioVentures, GP, LLC, BVF Partners LP, Aspire Capital Partners, LLC
ALPINE IMMUNE SCIENCES, INC. 
